Alliance Global Partners Maintains Buy on PDS Biotechnology, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Alliance Global Partners has maintained a Buy rating on PDS Biotechnology and raised its price target from $5 to $7.
August 20, 2024 | 4:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alliance Global Partners has reaffirmed its Buy rating on PDS Biotechnology and increased the price target from $5 to $7, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and an increased price target from a reputable firm like Alliance Global Partners suggests positive expectations for PDS Biotechnology's future performance. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100